아자타딘
Azatadine | |
| 임상 데이터 | |
|---|---|
| 상호 | 옵티마인 |
| AHFS/Drugs.com | Micromedex 상세 소비자 정보 |
| ATC 코드 | |
| 식별자 | |
| |
| CAS 번호 | |
| PubChem CID | |
| IUPHAR/BPS | |
| 드러그뱅크 | |
| 켐스파이더 | |
| 유니 | |
| 케그 | |
| 체비 | |
| 첸블 | |
| CompTox 대시보드 (EPA ) | |
| 화학 및 물리 데이터 | |
| 공식 | C20H22N2 |
| 몰 질량 | 290.199g/140−1 |
| 3D 모델(JSmol) | |
| |
| |
| (표준) | |
아자타딘(Optimine)은 1973년 [1][2]셰링플라우가 출시한 1세대 항히스타민제 및 항콜린제다.
1967년에 [3]특허를 받았습니다.그것은 로라타딘과 데슬라타딘 [4]: 53 둘 다에 의해 계승되었다.마케팅 승인이 광범위하게 [5][6][7][8]: 290 [9]철회되었습니다.
「 」를 참조해 주세요.
레퍼런스
- ^ Katelaris C (December 1990). "Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis". Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–7. PMID 1982614.
- ^ Small P, Barrett D, Biskin N (February 1990). "Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation". Annals of Allergy. 64 (2 Pt 1): 129–31. PMID 1968324.
- ^ US 3326924, Villani FJ, Caldwell W, "Azatadine", 1967년 발행
- ^ Horak F (2010). "Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4". In Pawankar R, Holgate ST, Rosenwasser LJ (eds.). Allergy Frontiers:Therapy and Prevention. Allergy Frontiers. Vol. 5. Springer Science & Business Media. ISBN 9784431993629.
- ^ "Azatadine". Drugs.com.
- ^ Food and Drug Administration (2005). "Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications". Federal Register 70 FR 10651.
- ^ Food and Drug Administration (2007). "Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions". Federal Register 72 FR 8184.
- ^ "Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals" (PDF). Department of Economic and Social Affairs of the United Nations Secretariat. New York: United Nations. 2005.
- ^ "OGD Suitability Tracking Report (Sorted by Drug Name)". FDA.
